详情页 - 河北医科大学第四医院机构库

资源类型：

文章类型：

作者：

Shi, Yuankai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] * ; Fang, Jian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Shu, Yongqian[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Wang, Donglin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Yu, Huiqing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Zhao, Yanqiu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Zhang, Liangming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Zhu, Bo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Li, Xingya[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Chen, Gongyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Shi, Jianhua[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Zheng, Rongsheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Huang, Jian'An[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Yang, Sheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Long, Jieran[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Gao, Wen[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Greco, Michael[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Wang, Jing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ; Li, Xiao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17] ;

机构： [1]Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China [2]Beijing Canc Hosp, Beijing, Peoples R China [3]Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China [4]Chongqing Canc Hosp, Chongqing, Peoples R China [5]Henan Prov Canc Hosp, Zhengzhou, Henan, Peoples R China [6]Yantai Yuhuangding Hosp, Yantai, Peoples R China [7]Army Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China [8]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [9]Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China [10]Shandong Linyi Tumor Hosp, Linyi, Shandong, Peoples R China [11]Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China [12]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China [13]Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [14]Peking Union Med Coll, Beijing, Peoples R China [15]Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China [16]BetaPharma, Princeton, NJ USA [17]BetaPharma, Shanghai, Peoples R China

出处：

ISSN：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2019]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China [2]Beijing Canc Hosp, Beijing, Peoples R China [3]Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China [4]Chongqing Canc Hosp, Chongqing, Peoples R China [5]Henan Prov Canc Hosp, Zhengzhou, Henan, Peoples R China [6]Yantai Yuhuangding Hosp, Yantai, Peoples R China [7]Army Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China [8]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China [9]Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China [10]Shandong Linyi Tumor Hosp, Linyi, Shandong, Peoples R China [11]Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China [12]Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China [13]Chinese Acad Med Sci, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [14]Peking Union Med Coll, Beijing, Peoples R China [15]Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China [16]BetaPharma, Princeton, NJ USA [17]BetaPharma, Shanghai, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A phase I study to evaluate safety, tolerability, pharmacokinetics and antineoplastic activity of BPI-7711 in patients with EGFR/T790M mutation advanced or recurrent NSCLC.

文献详情